# Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+

> **NCT01755325** · PHASE3 · SUSPENDED · sponsor: **Junmin Li** · enrollment: 680 (estimated)

## Conditions studied

- Chronic Myelogenous Leukemia

## Interventions

- **DRUG:** Compound realgar natural indigo Tablet
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01755325
- **Lead sponsor:** Junmin Li
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2012-11
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 680 (ESTIMATED)
- **Why stopped:** not enough patients
- **Last updated:** 2018-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01755325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01755325, "Phase III Study of Compound Formula Realgar-Indigo Naturalis Plus Imatinib Versus Placebo Plus Imatinib in Adult CML-CP Patients With Ph+". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01755325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*